title: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.
abstract: OBJECTIVE
  Topiramate is effective as adjunctive treatment of partial-onset seizures in adults. The efficacy and safety of topiramate as adjunctive therapy for the treatment of primary generalized tonic-clonic (PGTC) seizures were investigated in a randomized, double-blind, placebo-controlled study.
  
  
  METHODS
  Eighty patients, 3 to 59 years old, who experienced three or more PGTC seizures during an 8-week baseline phase were randomly assigned to treatment with either topiramate (n = 39) or placebo (n = 41). Topiramate was titrated to target doses of approximately 6 mg/kg/day over 8 weeks and maintained for another 12 weeks.
  
  
  RESULTS
  The median percentage reduction from baseline in PGTC seizure rate was 56.7% for topiramate patients and 9.0% for placebo patients (p = 0.019). The proportion of patients with 50% or higher reduction in PGTC seizure rate was 22/39 (56%) and 8/40 (20%) for the topiramate and placebo groups, respectively (p = 0.001). The median percentage reduction in the rate of all generalized seizures was 42.1% for topiramate patients and 0.9% for placebo patients (p = 0.003). The proportions of patients with 50% or higher reductions in generalized seizure rate were 18/39 (46%) and 7/41 (17%) for the topiramate and placebo groups, respectively (p = 0.003). The most common adverse events were somnolence, fatigue, weight loss, difficulty with memory, and nervousness. Treatment-limiting adverse events occurred in one patient in the topiramate group (anorexia and weight loss) and one in the placebo group (granulocytopenia and thrombocytopenia).
  
  
  CONCLUSIONS
  Topiramate is well-tolerated and effective for the adjunctive treatment of PGTC seizures.
authors.affiliation: Arkansas Epilepsy Program, Little Rock 72205, USA. vbiton@worldnet.att.net
authors.forename: V
authors.initials: V
authors.lastname: Biton
authors.forename: G D
authors.initials: GD
authors.lastname: Montouris
authors.forename: F
authors.initials: F
authors.lastname: Ritter
authors.forename: J J
authors.initials: JJ
authors.lastname: Riviello
authors.forename: R
authors.initials: R
authors.lastname: Reife
authors.forename: P
authors.initials: P
authors.lastname: Lim
authors.forename: G
authors.initials: G
authors.lastname: Pledger
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D000077236:Topiramate
chemical_list: D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose